Logo image of ALVAL.PA

VALBIOTIS SA (ALVAL.PA) Stock Price, Quote, News and Overview

EPA:ALVAL - Euronext Paris - Matif - FR0013254851 - Common Stock - Currency: EUR

0.878  0 (-0.23%)

ALVAL.PA Quote, Performance and Key Statistics

VALBIOTIS SA

EPA:ALVAL (6/18/2025, 7:00:00 PM)

0.878

0 (-0.23%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High1.9
52 Week Low0.88
Market Cap13.97M
Shares15.91M
Float15.25M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)10-27 2025-10-27
IPO06-07 2017-06-07


ALVAL.PA short term performance overview.The bars show the price performance of ALVAL.PA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -10 -20 -30

ALVAL.PA long term performance overview.The bars show the price performance of ALVAL.PA in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of ALVAL.PA is 0.878 EUR. In the past month the price decreased by -19.74%. In the past year, price decreased by -37.29%.

VALBIOTIS SA / ALVAL Daily stock chart

ALVAL.PA Competitors/Peers

The largest stocks on the EU markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
1ABBV.MI ABBVIE INC 18.69 293.65B
4AB.DE ABBVIE INC 18.27 286.51B
AMG.DE AMGEN INC 14.05 135.61B
GIS.DE GILEAD SCIENCES INC 14.05 116.93B
VX1.DE VERTEX PHARMACEUTICALS INC N/A 99.95B
1REGN.MI REGENERON PHARMACEUTICALS 11.98 49.56B
ARGX.BR ARGENX SE 102.34 28.87B
22UA.DE BIONTECH SE-ADR N/A 21.85B
IDP.DE BIOGEN INC 8.09 16.21B
1EXEL.MI EXELIXIS INC 18.93 9.81B
1MRNA.MI MODERNA INC N/A 8.71B
0QF.DE MODERNA INC N/A 8.64B

About ALVAL.PA

Company Profile

ALVAL logo image Valbiotis SA engages in the products and candidate drugs designed to prevent metabolic diseases. The company is headquartered in Perigny, Nouvelle-Aquitaine. The company went IPO on 2017-06-07. The firm specializes in developing nutrition solutions designed to prevent cardiometabolic diseases and provide nutritional support for patients. The company seeks to develop solutions designed to prevent type 2 diabetes, NASH, (non-alcoholic steatohepatitis) and obesity and to offer nutritional support. The firm prevents disease by developing products that reduce the risk factors of irreversible chronic diseases. The company provides patient support through new-generation medical nutrition solutions containing patented substances with clinically proven effects. Its products are plant-based and undergo strict scientific and clinical tests in collaboration with academic research centers.

Company Info

VALBIOTIS SA

12F rue Paul Vatine

Perigny NOUVELLE-AQUITAINE FR

Employees: 52

ALVAL Company Website

ALVAL Investor Relations

VALBIOTIS SA / ALVAL.PA FAQ

What is the stock price of VALBIOTIS SA today?

The current stock price of ALVAL.PA is 0.878 EUR. The price decreased by -0.23% in the last trading session.


What is the ticker symbol for VALBIOTIS SA stock?

The exchange symbol of VALBIOTIS SA is ALVAL and it is listed on the Euronext Paris - Matif exchange.


On which exchange is ALVAL.PA stock listed?

ALVAL.PA stock is listed on the Euronext Paris - Matif exchange.


What is the price forecast or stock price prediction for VALBIOTIS SA stock?

11 analysts have analysed ALVAL.PA and the average price target is 3.43 EUR. This implies a price increase of 291.12% is expected in the next year compared to the current price of 0.878. Check the VALBIOTIS SA stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is VALBIOTIS SA worth?

VALBIOTIS SA (ALVAL.PA) has a market capitalization of 13.97M EUR. This makes ALVAL.PA a Nano Cap stock.


How many employees does VALBIOTIS SA have?

VALBIOTIS SA (ALVAL.PA) currently has 52 employees.


What are the support and resistance levels for VALBIOTIS SA (ALVAL.PA) stock?

VALBIOTIS SA (ALVAL.PA) has a resistance level at 0.97. Check the full technical report for a detailed analysis of ALVAL.PA support and resistance levels.


Is VALBIOTIS SA (ALVAL.PA) expected to grow?

The Revenue of VALBIOTIS SA (ALVAL.PA) is expected to decline by -96.57% in the next year. Check the estimates tab for more information on the ALVAL.PA EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy VALBIOTIS SA (ALVAL.PA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does VALBIOTIS SA (ALVAL.PA) stock pay dividends?

ALVAL.PA does not pay a dividend.


When does VALBIOTIS SA (ALVAL.PA) report earnings?

VALBIOTIS SA (ALVAL.PA) will report earnings on 2025-10-27.


What is the Price/Earnings (PE) ratio of VALBIOTIS SA (ALVAL.PA)?

VALBIOTIS SA (ALVAL.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.66).


ALVAL.PA Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

ALVAL.PA Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to ALVAL.PA. ALVAL.PA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ALVAL.PA Financial Highlights

Over the last trailing twelve months ALVAL.PA reported a non-GAAP Earnings per Share(EPS) of -0.66. The EPS increased by 22.69% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -34.58%
ROE -53.12%
Debt/Equity 0.24
Chartmill High Growth Momentum
EPS Q2Q%-38.62%
Sales Q2Q%-99.17%
EPS 1Y (TTM)22.69%
Revenue 1Y (TTM)-88%

ALVAL.PA Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 85% to ALVAL.PA. The Buy consensus is the average rating of analysts ratings from 11 analysts.

For the next year, analysts expect an EPS growth of -4.38% and a revenue growth -96.57% for ALVAL.PA


Ownership
Inst Owners2.25%
Ins Owners4.45%
Short Float %N/A
Short RatioN/A
Analysts
Analysts85.45
Price Target3.43 (290.66%)
EPS Next Y-4.38%
Revenue Next Year-96.57%